|Bid||75.50 x 800|
|Ask||75.53 x 2200|
|Day's Range||74.28 - 76.46|
|52 Week Range||50.71 - 84.37|
|Beta (3Y Monthly)||1.84|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 24, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||80.15|
Seattle Genetics (SGEN) delivered earnings and revenue surprises of 38.46% and 14.25%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Seattle Genetics stock popped late Tuesday after the biotech company topped second-quarter revenue estimates. But the company's losses per share were deeper than expected for the period.
-Record ADCETRIS® Net Sales in U.S. and Canada of $159.0 Million in the Second Quarter, an Increase of 30 Percent Over the Second Quarter of 2018-
NEW YORK, NY / ACCESSWIRE / July 16, 2019 / Seattle Genetics, Inc. (NASDAQ: SGEN ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 16, 2019 at 4:30 PM ...
TOKYO and BOTHELL, Wash., July 16, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seattle Genetics, Inc. (SGEN) today announced submission of a Biologics License Application for accelerated approval to the U.S. Food and Drug Administration for the investigational agent enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who have received a PD-1/L1 inhibitor and who have received a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. The submission is based on results from the first cohort of patients in the EV-201 pivotal phase 2 clinical trial that were presented as a late-breaking abstract at the annual meeting of the American Society of Clinical Oncology (ASCO) in June.
Seattle Genetics, Inc. (SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced submission of a Biologics License Application for accelerated approval to the U.S. Food and Drug Administration for the investigational agent enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who have received a PD-1/L1 inhibitor and who have received a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. The submission is based on results from the first cohort of patients in the EV-201 pivotal phase 2 clinical trial that were presented as a late-breaking abstract at the annual meeting of the American Society of Clinical Oncology (ASCO) in June.
Last week was a quiet one for the biotech space with the exception of a few clinical trial readouts . Pharma and biotech stocks took comfort in a ruling by a federal judge that went against President Donald ...
Attractive stocks have exceptional fundamentals. In the case of Seattle Genetics, Inc. (NASDAQ:SGEN), there's is a...
President and CEO of Seattle Genetics Inc (SGEN) Clay B Siegall sold 20,148 shares of SGEN on 07/08/2019 at an average price of $66.89 a share.
Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seattle Genetics, Inc. announced today that it will report its second quarter 2019 financial results on Tuesday, July 16, 2019 after the close of financial markets. Following the announcement, management will host a conference call and webcast discussion of the results and provide a general corporate update.
INCLINE VILLAGE, Nev., June 24, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (PDLI) announces that at its 2019 annual meeting of stockholders held June 20, 2019, the Company's stockholders elected Natasha A. Hernday to the Company's Board of Directors. The Company also announced that its stockholders voted to re-elect Harold E. Selick, Ph.D. and Samuel R. Saks, M.D. as Directors, and approved, on an advisory basis, executive officer compensation.
Puget Sound Business Journal has named Clay Sigall its Middle Market Dealmaker of the Year for the inaugural Middle Market Fast 50 event and section.
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Jeff Ubben, George Soros and Carl Icahn think. Those hedge fund operators make billions of […]
Seattle Genetics Inc NASDAQ/NGS:SGENView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for SGEN with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on May 29. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding SGEN is favorable, with net inflows of $4.58 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Roche's (RHHBY) oncology portfolio gets a boost with the approval of Rozlytrek for neurotrophic tyrosine receptor kinase fusion-positive, advanced recurrent solid tumors.
Clay Siegall became the CEO of Seattle Genetics, Inc. (NASDAQ:SGEN) in 2002. This analysis aims first to contrast CEO...
-Data Presentations Highlight Continued Advances in Research for Treating Blood Cancers-
Roche's (RHHBY) hematology portfolio gets a boost as FDA approves Polivy for DLBCL, and lymphoma drug, Gazyva, meets goals in a phase II study.